News
Despite US tariff concerns, India's pharmaceutical exports are projected to double to $65 billion by 2030. This growth is ...
3h
TipRanks on MSNCipla Ltd Announces Strong Q1 2025 Financial ResultsCipla Ltd ( ($IN:CIPLA) ) has provided an announcement. Cipla Ltd has released its unaudited financial results for the quarter ended June 30, ...
The Sensex fell 721 points and the Nifty 50 dropped 225 points amid foreign fund withdrawals. Analysts predict upcoming ...
Bank of Baroda reported net profit at Rs 4,541 crore for Q1 FY26. This marks a 2 percent rise from the Rs 4,458 crore net ...
Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.
Balkrishna Industries, Lodha Developers, Whirlpool, ZEN Technologies, and SBFC Finance are also to release their April-June ...
Total Income from operations rose to Rs 6,957 crore for the June quarter as compared with Rs 6,694 crore in the year-ago ...
Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...
Porvorim: Blaming govt for doing little to ensure employment opportunities for locals, legislators on Friday said that ...
Indian pharmaceutical company, Cipla, aims to reach $1 billion in US sales by FY27, driven by upcoming product launches.
Cipla reported a 10% rise in Q1 PAT to ?1,298 crore, driven by India, Europe, and Africa sales. Revenue grew to ?6,957 crore despite a North America dip.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results